First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma | Naviance

First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma

First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma

A novel treatment approach using combination immunotherapy before and after surgery shows promise for patients with operable mesothelioma, according to a new study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

LEARN MORE

Recent Posts

After a year of turmoil, cancer researchers see promising signs for mRNA vaccines AI and Mammograms Single Nutrient Fuels Cancer-Fighting Power of T Cells Alcohol and Cancer Risk Colon Cancer Screening: What You Need to Know Detecting Early-Stage Cancers with a New Blood Test Measuring Epigenetic Instability Oral Bacterium May Promote Breast Cancer Development and Spread Extra Copies of Chromosome 1q May Drive Pancreatic Cancer How Bacteria May Promote Breast Cancer